Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC

15 de novembro de 2026 atualizado por: Shanghai Zhongshan Hospital

A Single-Arm, Multicenter Phase Ib Study on the Efficacy and Safety of IBI310 in Combination With Bevacizumab and Sintilimab for First-Line Treatment of Advanced Hepatocellular Carcinoma

This is a single-arm, multicenter phase Ib study to evaluate the effectiveness and safety of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.

Visão geral do estudo

Descrição detalhada

This is a single-arm, multicenter phase Ib study evaluating the safety and efficacy of IBI310 combined with sintilimab and bevacizumab in advanced hepatocellular carcinoma. Patients will receive IBI310 1.0 mg/kg IV on day 1 every 6 weeks plus sintilimab 200 mg IV and bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Approximately 50 patients are planned. After the first 6-10 patients are treated, the Safety Monitoring Committee (SMC) will assess safety in this subgroup and determine whether enrollment should continue.

Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, loss to follow-up, death, or other protocol-defined discontinuation, whichever occurs first, for a maximum of 24 months. Patients with initial investigator-assessed radiographic progression per RECIST v1.1 may continue study treatment if clinically stable, likely to benefit, and willing to continue; tumor response will then be assessed by iRECIST until no further benefit per investigator, intolerable toxicity, new antitumor therapy, consent withdrawal, loss to follow-up, or maximum treatment duration, whichever occurs first.

Tipo de estudo

Intervencional

Inscrição (Estimado)

50

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Histologically/cytologically confirmed hepatocellular carcinoma, or meeting the clinical diagnostic criteria for hepatocellular carcinoma ;
  2. Aged ≥18 years,≤75 years;
  3. ECOG performance status score of 0 or 1 point;
  4. Barcelona Clinic Liver Cancer (BCLC) stage C, or Stage B not suitable for radical surgery and/or local treatment;
  5. No systemic antitumor treatment for hepatocellular carcinoma before the first administration;
  6. At least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1), or measurable lesion with definite progression after local treatment (based on RECIST V1.1 criteria), at least 4 weeks before enrollment (for those who received local radioisotope therapy, at least 3 months)
  7. Child-Pugh Class A or B(≤7);
  8. Adequate organ and bone marrow function.
  9. Expected life time is over 12 weeks.
  10. Take effective contraceptive measures
  11. Willing to attend the study and having given the ICF

Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC
  2. History of hepatic encephalopathy or liver transplantation
  3. Pleural, ascites, and pericardial effusion with clinical symptoms requiring drainage
  4. HBV-DNA>2000 IU/ML or 10^4 copies/ml;Untreated positive HCV-RNA;HbsAg and anti-HCV antibody were both positive
  5. History of GI bleeding within 6 months, or severe (G3) varices at endoscopy within 3 months
  6. Arteriovenous embolism within 6 months
  7. The tumor thrombus involved both main and branch portal veins, main portal veins and mesenteric veins or inferior vena cava.
  8. Antiplatelet drugs were administered for 10 days for therapeutic purposes 2 weeks before administration
  9. Uncontrolled hypertension
  10. Unrecovered AE(>CTCAE grade 1) due to previous treatment
  11. Heart failure (NYHA Classification III-IV), or poorly controlled arrhythmias
  12. History of gastrointestinal perforation, fistula, intestinal obstruction, extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
  13. With lung fibrosis, interstitial lung disease, pneumoconiosis, drug-associated pneumonia and serious impairment in lung function
  14. Active tuberculosis
  15. Infected with HIV or syphilis
  16. Severe infections that are active or clinically poorly controlled
  17. Use of immunosuppressive drugs within 4 weeks prior to initial dosing
  18. Receipt of live attenuated vaccine within 4 weeks prior to randomization
  19. Significant traumatic injury or major surgical procedure within 28 days prior to randomization
  20. Other conditions that the investigator judged inappropriate for inclusion
  21. Prior immunotherapy or targeted therapy
  22. Treatment of Traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects whitin 2 weeks
  23. Pregnant or breast-feeding women

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Single-Arm

IBI310 1mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1,Q3W

IBI310 1mg/kg IV d1 Q6W

sintilimab 200 mg IV d1 Q3W

Outros nomes:
  • IBI308

bevacizumab 15 mg/kg IV d1,Q3W

Outros nomes:
  • IBI305

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Treatment Emergent Adverse Event, TEAE
Prazo: Any emergent adverse event from first dose through study completion, up to 2 years.

Safety

Any emergent adverse event from first dose through study completion, up to 2 years.
Severe Adverse Event, SAE
Prazo: Any severe adverse event from first dose through study completion, up to 2 years.

Safety

Any severe adverse event from first dose through study completion, up to 2 years.
Objective response rate (ORR)
Prazo: The proportion of patients with complete response or partial response, through study completion, up to 2 years

efficacy

The proportion of patients with complete response or partial response, through study completion, up to 2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Duration of Response(DOR)according to RECIST V1.1 criteria
Prazo: From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months

efficacy

From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
Duration of Response(DOR)according to mRECIST criteria
Prazo: From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months

efficacy

From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
Disease Control Rate(DCR) according to RECIST V1.1 criteria
Prazo: The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years

efficacy

The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
Disease Control Rate(DCR) according to mRECIST criteria
Prazo: The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years

efficacy

The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
Objective response rate (ORR) according to mRECIST criteria
Prazo: The proportion of patients with complete response or partial response, through study completion, an average of 2 years

efficacy

The proportion of patients with complete response or partial response, through study completion, an average of 2 years
Progresison Free Survival(PFS)according to RECIST V1.1 criteria
Prazo: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months

efficacy

From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
Progresison Free Survival(PFS)according to mRECIST criteria
Prazo: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months

efficacy

From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
Overall survival (OS)
Prazo: From the date of randomization until death from any cause, assessed up to 48 months.

efficacy

From the date of randomization until death from any cause, assessed up to 48 months.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Zhenggang Ren, Shanghai Zhongshan Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de março de 2025

Conclusão Primária (Estimado)

1 de janeiro de 2029

Conclusão do estudo (Estimado)

1 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

14 de abril de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

5 de maio de 2022

Primeira postagem (Real)

6 de maio de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever